Editorial: Unraveling Osteoarthritis Pathogenesis: New Insights Into Preradiographic Disease and Patient Phenotypes
L. Deveza,David J. Hunter
DOI: https://doi.org/10.1002/art.39439
2015-09-01
Arthritis & Rheumatology
Abstract:The burden of osteoarthritis (OA) worldwide is skyrocketing, overloading already strained health care systems (1). With the impact of increasing obesity and aging, the lifetime risk of symptomatic knee OA is estimated to be ;45% (2). The direct costs of this chronic disease are dominated by total knee joint replacement, the prevalence of which currently exceeds that of rheumatoid arthritis and is similar to that of congestive heart failure (3). It was not until recently that the OA research community directed a shift toward new treatment models aimed at halting joint damage rather than the palliative approach of analgesic treatment followed by joint replacement. However, the sequential failures of novel disease-modifying treatment strategies attempting to target diverse pathogenic mechanisms have highlighted the need to target early disease and to better identify and target distinct disease phenotypes. Distinguishing particular subtypes, in which different patterns of joint involvement may be present, could contribute to the understanding of the complex nature and heterogeneity of OA. In addition, it may enlighten a more tailored and successful approach to development of therapies that are more specific to the disease process. For example, if one successfully demonstrates that the process of OA at a particular stage is predominantly driven by high bone turnover in a certain group of patients, while in others synovial inflammation is the hallmark of joint damage, it may be that different treatments can benefit one group but not the other. In this regard, it is possible that success of previous clinical trials has been hampered by inclusion of the typically heterogeneous OA population rather than the inclusion of specific targeted-phenotype patients. Furthermore, it has been shown that the majority of patients experience minimum or slow rates of structural progression over time, while in a small subgroup there is rapid deterioration of the joint (4). Identifying these faster-progression phenotypes would allow directing greater treatment efforts to these patients and also prioritizing their inclusion in clinical trials, thus enhancing the trials’ efficiency. From the pathophysiologic perspective, the existence of different phenotypes would suggest distinct underlying causes, whether hormonal, metabolic, environmental, or genetic, leading to the common end-pathology that we know as OA. However, in a disorder in which multiple tissue pathologies frequently coexist and are strongly interconnected (particularly synovitis, changes in bone remodeling, and meniscus and cartilage damage), disentangling the earliest phases of the disease provides a unique opportunity to examine these alternative pathogenic pathways during the disease’s inception. Increasing attention has been given to identification of the earliest stages of OA, which Supported by the National Health and Medical Research Council (program grant APP1091302). Leticia A. Deveza, MD, David J. Hunter, MBBS, PhD: Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute of Medical Research, and University of Sydney, Sydney, New South Wales, Australia. Dr. Hunter has received honoraria for advisory board service from Abbott, Flexion, and Merck Serono (less than $10,000 each) and royalties from DJO Global from a license agreement related to a patellofemoral sleeve. Address correspondence to David J. Hunter, MBBS, PhD, Rheumatology Department, Royal North Shore Hospital, Reserve Road, St. Leonards, New South Wales 2065, Australia. E-mail: david. hunter@sydney.edu.au. Submitted for publication September 6, 2015; accepted in revised form September 10, 2015.